CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition.
CEF19, Epstein-Barr Virus latent NA-3A 458-466, is a synthetic peptide corresponding to a defined epitope sequence derived from the latent nuclear antigen 3A (NA-3A) of Epstein-Barr Virus (EBV). As a peptide reagent, it is widely recognized for its utility in immunological research focused on viral infection, antigen-specific T cell responses, and epitope mapping. The sequence represents a conserved region within EBV, making it a valuable tool for dissecting host-pathogen interactions and for studying immune recognition mechanisms in the context of persistent viral infections. Its biochemical properties enable precise experimental manipulation and facilitate reproducible research outcomes in both basic and applied virology.
Epitope mapping: The peptide is extensively applied in fine-mapping of antigenic determinants recognized by cytotoxic T lymphocytes (CTLs) in EBV-infected hosts. By serving as a defined target, the sequence enables researchers to delineate the specificity and breadth of T cell responses against EBV latent antigens. This is critical for advancing the understanding of viral immune evasion strategies and for identifying immunodominant regions that are relevant to vaccine or immunotherapy development.
T cell activation assays: In immunological studies, the peptide is utilized to stimulate peripheral blood mononuclear cells (PBMCs) or isolated T cell populations in vitro. Its defined sequence allows for the assessment of antigen-specific T cell activation, cytokine production, and proliferation. These assays are instrumental in evaluating cellular immunity to EBV, characterizing T cell receptor (TCR) repertoire diversity, and monitoring immune competence in various experimental models.
Immunomonitoring: The reagent plays a pivotal role in tracking EBV-specific immune responses in longitudinal studies or clinical research settings. By incorporating the peptide into ELISPOT, intracellular cytokine staining, or multimer staining protocols, investigators can quantify the frequency and functionality of epitope-specific T cells. This application is particularly valuable for monitoring immune reconstitution, evaluating vaccine candidates, or assessing the impact of immunomodulatory interventions in EBV-associated diseases.
Peptide-MHC binding studies: The defined sequence of this EBV-derived peptide makes it suitable for investigating peptide-MHC class I binding affinities and stabilities. Such studies are essential for elucidating the molecular determinants of antigen presentation, optimizing peptide-based immunogens, and refining predictive algorithms in computational immunology. The peptide's compatibility with various MHC alleles further enhances its utility in comparative immunogenetics research.
Analytical tool in peptide synthesis validation: As a well-characterized epitope, the peptide also serves as a reference standard in analytical quality control during peptide synthesis or purification workflows. Its use in mass spectrometry, HPLC, or immunoreactivity assays supports method validation, batch consistency assessment, and troubleshooting in peptide manufacturing processes. This contributes to ensuring the reliability of peptide reagents deployed in downstream immunological or virological studies.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More